Over the past five years, almost half of drug launches have fallen short of their sales forecasts due to misjudged pricing and reimbursement (P & R) risks, resulting in significant financial losses for developers. At MARA Rating Company, we have been developing an independent, data-driven assessment of Market Access Risk for drugs introduced since 2020, with over 350 free sample ratings available and growing.

What makes MARA stand out?

• Achieving a 97% precision rate and minimal false-positives, ensuring you steer clear of investments that may not secure reimbursement.
• Utilizing an A++ to C scale within our ten-domain HTA framework, in alignment with global payer standards.
• Providing swift turnarounds on Deep Dives and Custom Reports to mitigate risks in today’s fast-paced deal environment.

Do not allow Market Access challenges to hinder your investments. Request a MARA Deep Dive to compare your assets against real-world payer decisions and protect your future deals.

For more information, visit our MARA Rating List page: https://lnkd.in/daKuQVYX

Contact us at 📩 sales@mararating.com | www.mararating.com for an independent, thorough, and board-level clarity assessment.